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Summary: A radioimmunoassay for the determination of pig pancreatic kallikrein was developed. The chloramine-T
method was employed for the labelling of the antigen with 12SI. The assay allows the determination of kallikrein in
concentrations as low as 0.4 /zg/1. Pig urinary and pig submandibular kallikreins are indistinguishable from pig
pancreatic kallikrein by the assay. No cross reactivity was observed for bovine trypsin and chymotrypsin,
porcine trypsin and kallikreins of guinea pig submandibular glands and guinea pig coagulation glands. Because of
the high specificity of the assay, which is not attainable with conventional assays based on the enzymatic activity,
the radioimmunoassay is highly suited for investigations into the physiological role and the pharmacological
mechanism of action of pig glandular kallikreins.
Entwicklung eines Radioimmunoassay s für Kallikrein aus Schweinepankreas
Zusammenfassung: Für die Bestimmung von Schweinepankreaskallikrein wurde ein Radioimmunoassay entwickelt.
Die Markierung des Antigens mit 12SJ erfolgte nach der Chloramin-T-Methode. Der Radioimmunoassay gestattet die
Bestimmung von Kallikrein in Konzentrationen bis herab zu 0,4 jug/1. Kallikreine aus Schweineharn und Schweine-
submandibularisdrüsen sind im Radioimmunoassay nicht von Schweinepankreaskallikrein zu unterscheiden. Keiner-
lei Kreuzreaktion wurde für Trypsin (Rind, Schwein), Chymotrypsin (Rind) und Kallikreine aus Submandibularis-
drüsen und Koagulationsdrüsen von Meerschweinchen gefunden. Auf Grund der hohen Spezifltät der Bestimmungs-
methode, die mit konventionellen, auf der enzymatischen Aktivität beruhenden Methoden nicht erreicht wird, ist
der Radioimmunoassay bestens geeignet für Untersuchungen über die physiologische Funktion und den pharmako-
logischen Wirkungsmechanismus von Schweinepankreaskallikrein.
Introduction
The determination of kallikrein is usually achieved by
measuring the rate of hydrolysis either of synthetic
substrates or of the natural substrate kininogen (1—3).
These assays are not specific for kallikrein, because they
also detect other proteases. For studies on the physiolog-
ical function and the pharmacological mechanism of
action of kallikrein, which include the measurement of
the enzyme in tissues and body fluids, a more specific
assay is required. This requirement is met by the radio^
irhmunoassay technique, which is based on the compe-
titive inhibition of the binding of labelled antigen to its
specific antibody by the unknown or by the unlabelled
antigen used as a standard.
By employing this method an assay was developed, with
a sensitivity (lower detection limit 40—300 pg) as high
as that of the most sensitive enzymatic assays (1).
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The radioimmunoassay is specific for pig kallikreins of
pancreas, urine and submandibular gland. All other
proteinases investigated so far do not interfere in the
assay.
Materials and Methods
Pig pancreatic kallikrein used for radioiodination and as a
standard in the radioimmunoassay was a highly purified
neuraminidase-treated preparation (3) kindly provided by
Dr. F. Fiedler, Munich. Pig trypsin, Merck, Cat. No. 8350;
cristalline bovine trypsin, Novo Industri; guinea pig coagula-
tion gland kallikrein and guinea pig submandibular kallikrein
were gifts from Dr. C. Moriwaki, Tokyo and Dr. M. Lemon,
Bristol. Pig urinary kallikrein and pig submandibular kalli-
krein preparations were isolated as described (4, 5). Rabbit
anti-kallikrein serum was a gift of Bayer AG, Wuppertal;
donkey anti-rabbit IgG serum was purchased from Wellcome
Company, Cat, No. RD 17.
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Buffers
Buffer A: 0.015 mol/1 NaH2PO4, 0.15 mol/1 NaCl, 200 mg
Merthiolate, 2 g/1 bovine serum albumin, O. l mol/1 EDTA,
pH 7.4;
Buffer B: 0.015 mol/1 NaH2PO4,0.15 mol/1 NaCl, 200 mg/1
Merthiolate, 40 g/1 bovine serum albumin, pH 7.4;
Buffer C: 0.015 mol/1 NaH2PO4,0.15 mol/1 NaCl, pH 7.4.
Radioiodination
The modification of the chloramine T method of Greenwood
& Hunter (6) described by Erhardt et al. (7) was used for the
radioiodination of kallikrein. All reagents were dissolved in
buffer C. The reaction was started by adding 10 μΐ (18.5 MBq =
0.5 mCi) Na125I and 10 μΐ (30 Mg) chloramine-T to 5 μΐ (2.5 Mg)
kallikrein solution. After 5-10 s of mixing the reaction was
stopped by 20 μΐ (60 Mg) sodium metabisulfite. The reaction
mixture was then transferred to a Sephadex G-75 column
1.2 X 14 cm, the reaction vial was washed once with 50 μΐ of a
10 g/1 potassium iodide solution. The column was eluted with
buffer C (40 ml/h), and 0.8 ml fractions were collected into
disposable polypropylene tubes containing 50 μΐ of buffer B.
The radioactivity of the fractions was determined and the 4-6
fractions with the highest radioactivity of the peak correspond-
ing to the elution volume of kallikrein were pooled and diluted
with buffer A to a concentration of 250 000 counts/min · ml
for use in the radioimmunoassay.
Radioimmunoassay conditions
Dilutions of kallikrein standard samples, unknowns, anti-rabbit
IgG serum and 125I4callikrein were prepared with buffer A.
70 mg/1 of rabbit IgG were added to the 12SI-kallikrein solution,
Anti-kallikrein serum was diluted with buffer B so as to give a
binding fraction of 0.50 12SI4callikrein under the conditions
employed in the radioimmunoassay.
The incubation mixtures were set up in disposable polypropylene
tubes following the scheme given in table 1. After an incubation
period of 24-48 h, 0.1 ml of the solution of anti-rabbit IgG
serum (diluted according the recommendation of the manu-
facturer) was added. After another 2-3 h, 0.5 ml buffer A were
added. After 10 min centrifugation at 6000 g the supernatant was
removed by aspiration and the radioactivities of the precipitates
were measured in a gamma counter. All calibration samples were
set up in quadruplicate.
Standard curves were obtained by plotting the fraction of bound
radioactivity, B-N (B: counts bound, B0: counts read for zero
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Results
Properties of I25l-labelled kallikrein
The chloramine-T method (6,7) was employed for the
iodination of kallikrein. the reaction mixture was imme-
diately subjected to gel filtration which effectively
separated the labelled kallikrein from uiire cted Na 125I
(fig. 1). In one experiment the immunologic l reactivity
of the fractions of the 125i-kallikrein peak was checked
by setting up titration curves for each fraction. Except
for the first fraction of the peak, with a maximum
binding of 0.28, no significant differences in the maxi-
mum binding (0.82 for all other fractions) and in the
slopes of the curves were observed. Therefore, for use
in the radioimmunoassay, usually the 4—6 fractions
representing the maximum of the -25I4callikrein peak
(fractions 11—15 in fig. 1) were pooled. The specific
radioactivity of the 125I-kallikrein preparations, cal-
culated from the radioactivity eluted in the kallikrein
peak, was 1.11-4.8 MBq/jug (30^130 μΟί/μ§), the mean
value ± standard deviation of 21 iodinations was 2.85 ±
0.93 MBq/Mg (77 ± 25 μ€ί^).
The 125I-labeIled kallikrein was used in the radioimmuno-
assay for up to five weeks. During this time the fraction
of radioactivity precipitable with an equal volume of
100 g/1 trichloroacetic acid decreases from 0.98 to about
0.80.
Figure 2 shows a typical titration curve. The maximum
binding of 21 125I-kallikrein preparations varied between
0.38 and 0.86 (0.68 ± 0.14, mean ± S.D.). Only prep-
arations with a maximum binding higher than 0.50 (20
out of 21 preparations) were used in the radioimmuno-
assay.
dose, N: nonspecifically bound counts), against ng kallikrein in a
linear-log mode. The assays were evaluated by means of a com-
puter employing the spline approximation method (8-10).
Specificity
The immunologic l reactivity of anti-kallikrein serum with other
proteases was checked by employing, per incubation tube, 10 ng
—100 Mg of bovine trypsin, bovine chymotrypsin, or porcine
trypsin; 0.1 ng-10 μg of kallikreins from guinea pig submandi-
bular and coagulation glands; and approximately 0.1-10 ng of
pig submandibular and pig urinary kallikrein.
Tab. 1. Preparation of radioimmunoassay incubation mixtures
The amounts of the solutions pipetted into polypropylene
disposable tubes are shown in the table.
Buffer A Buffer B Sample1) Anti- 12-sI4calli-
kallikrein krein
serum
l) Standard or unknowns
45000 -
40000
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Fig. 1. Separation of 125Ί labelled pig pancreatic kallikrein
(fractions 9—19) from unreacted Na 12SI on a Sephadex
G 75 column (1.2 X 14 cm).
Fraction volume: 0.8 ml, elution buffer: buffer C. The
radioactivity of the fractions was measured with geometry
adjusted to low counting efficiency. In this experiment
fractions 11—15 were pooled for use in the radioimmuno-
assay.
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Fig. 2. Antiserum titration curve.
The tubes, containing 200 μΐ buffer B, 100 μΐ anti-kalli-
krein serum dilution and 100 μΐ 125I-kallikrein
(28 000 counts/miii) were held at room temperature for
2 days. Bound 12SI-kallikrein was precipitated by the
addition of 100 μΐ of second antibody dilution. The anti-
serum dilutions given in the figure are the final dilutions
in the incubation mixture.
Kinetics of the binding of I2sl-kallikrein to the antibody
In order to find the optimal incubation conditions for
the routine radioimmunoassay the kinetics of the
binding of I2sl-kallikrein to the antibody was studied at
8,22 and 37° C. Figure 3 siunmarizes the results. The
lowest binding rate is observed at 8°C and, as indicated
by the shape of the curve, the endpoint is not yet reached
after 120 h. Both at 25 and 37° C equilibrium is reached
between 48 and 72 h; maximum binding at 37° C is
significantly lower than at 25°C.
0.60^
Precision
Both intraassay and interassay precision are dependent
on the concentration of kallikrein in the sample. In the
range of 0.3 to 5 ng per incubation mixture the coeffi-
cient of variation for quadruplicates is generally 6-10%.
For the interassay precision the coefficient of variation
for the same concentration range calculated from 6
consecutive assays was 6—15%.
Sensitivity
The lower detection limit is generally between 0.4 and
3.0 μg/l sample volume, depending on the quality of
the labelled kallikrein and the incubation conditions
(fig. 4).
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Fig. 3. Time and temperature-dependence of the binding of
12
^I-kailikrein to antibody.
Incubation mixtures correspond to B0 and Ν in Table 1.
The samples were held at 8 °C ·—·, 25 °C ο—α and
37 °C ο—ο. The incubation was stopped by freezing the
samples at - 78 °C. The frozen samples were stored at
- 21 °C. All samples were thawed simultaneously at
30 °C for 3 min and the second antibody was added to
precipitate the bound
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Fig. 4. Influence of preincubation on standard curves.
Reagents were used as summarized in Table 1. Incubation
conditions:
A: preincubation of tracer and anti-kallikrein serum for
42 h followed by 24 h after addition of standard
(Δ—Δ);
B: incubation of standard, anti-kallikrein serum and
tracer for 42 h (·—·);
C: preincubation of standard and anti-kallikrein serum
for 42 h followed by 24 h after addition of tracer.
-. — 0.90 intercept defined as lower detection
limit.
Specificity
In order to test the specificity of the antiserum several
serine proteases were evaluated with respect to their
capacity to inhibit competitively the binding of 125I-
kallikrein. Absolutely no cross reactivity was observed
for bovine trypsin and chymotrypsin, porcine trypsin
and guinea pig coagulation gland and submandibular
gland kallikrein applied in the concentrations described
above. The kallikreins of pig urine and pig submandibular
glands showed immunological reactivities (nearly)
identical to pig pancreatic kallikrein (fig. 5).
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Fig. 5. Cross reactivity of pig urinary kallikrein (o—o) and pig
submandibular kallikrein (o—a) in the radioimmuno-
assay for pig pancreatic kallikrein (·—·).
The exact concentration of urinary and submandibular
kallikreins was not known.
Discussion
The chloramine-T method (6,7), widely used for the
iodination of proteins, was successfully applied to
produce 125I-labelled pig pancreatic kallikrein. The
iodinated protein is stable, immunologically active and
of sufficiently high specific radioactivity for setting up
a sensitive radioimmun oassay. The stability of the
iodinated kallikrein was checked by determining the
amount of radioactivity bound to high molecular weight
protein: in four week old preparations a fraction of 0.8
of the radioactivity was still precipitable by trichloro-
acetic acid.
The immunological reactivity of kallikrein is not
seriously effected by the labelling procedure. If a
constant amount of freshly prepared 125I-kallikrein is
incubated with a series of antiserum dilutions (fig. 2),
the maximum binding is usually higher than 0.80; it
decreases for older preparations owing to the release of
low molecular weight radioactive substances, which are
not bound by the antibody. If these radioactive low
molecular weight fragments are removed by gel filtration
almost the same maximum binding is observed as for
fresh preparations. Nevertheless, the 125I-kallikreiais
not generally used for longer than five weeks, because
the sensitivity of the assay decreases with the age of the
preparation.
The results of the kinetic studies (fig. 3) of the binding
of 12SI-kaUikrein to the antibody at 8,25 and 37°C
show that incubation at room temperature (20—25 °C)
is preferable for the radioimmunoassay. At low temper-
atures the reaction is relatively slow, whereas at higher
temperatures the equilibrium is more in favour of
dissociation. We routinely incubate the samples at room
temperature for 36-^48 h. Under these conditions the
binding is close to equilibrium. In earlier experiments we
had observed a significant decrease of binding for in-
cubation periods longer than 72 h at all three temper-
atures investigated (11). We interpreted this effect as a
loss of immunological reactivity of the 12SI-kallikrein
and/or the antibody. Since, in our recent experiments,
we used the same antiserum but a different12^-kalli-
krein preparation and did not observe a significant
decrease of binding, it seems likely that properties of
the ^I^kallikrein and not of the antiserum were respon-
sible for this effect.
The sensitivity of radioimmunoassays can be increased
by preincubating unlabelled antigen with the antibody
before the labelled antigen is added. This technique
can also be employed successfully in the kallikrein
radioimmunoassay. As figure 4 demonstrates, prein-
cubation for 42 hours before addition of the labelled
antigen causes a shift of the standard curve toward
lower kallikrein concentrations and an increase of the
slope. The lower detection limit is reduced to one half
in figure 4 (with the 0.90 intercept defined as the lower
detection limit). In other experiments it was reduced
occasionally even to one fourth. For most of our
investigations this increased sensitivity is not required
and, because the total incubation time would be three
instead of two days, we do not apply the preincubation
method routinely.
The specificity of the test was examined by employing
a variety of serine proteases in the radioimmunoassay.
Because of the structural homology of pig pancreatic
kallikrein with other serine proteases (3) immunological
cross reactivity seems possible. However, it turned put
that only the kallikreins of pig submandibular gland and
pig urine show cross reactivity. No cross reactivity at all
was observed for bovine trypsin and chymotrypsin,
porcine trypsin and kallikreins of guinea pig submand-
ibular glands and guinea pig coagulation glands. The
(nearly) identical slope of the dose response curves
(fig. 5) indicates a high similarity if not identity of the
three porcine kallikreins in their immunological pro-
perties. With the antiserum we use it is impossible to
discriminate between the three enzymes by mearis of the
radioimmunoassay. This finding is in agreement with
results found by immunodiffusion and irnmunoelectro-
phoretic studies (12). Identical precipitation patterns
were obtained by the authors using the double diffusion
technique of Ouchteflony, when the three kallikreins
were allowed to diffuse against purified rabbit IgG
directed against any one of the kallikreins. In the immuno-
electrophoretic studies different electrophoretic mobilities
of the various kallikreins were observed but immunolog-
ical identity was indicated by the form, location and
confluence of the precipitin lines.
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Immunological similarity has also been demonstrated by
Geiger &Mann (13) and Ole-Moiyoi et al. (14) for human
saliva, pancreatic and urinary kallikreins using antibodies
directed against human urinary kallikrein and human
pancreatic extract, respectively.
The radioimmunoassay for pig pancreatic kallikrein was
developed with the aim of applying it in studies on the
pharmacological effects and the physiological role of this
enzyme. Both high specificity and sensitivity are pre-
requisites for an assay to be used in such studies, since
body fluids and tissues have to be examined which might
also contain other proteases. The radioimmunoassay
presented here is specific for pig glandular kallikreins.
However, a discrimination of the different pig glandular
kallikreins is not possible. This may cause difficulties in
some physiological studies where such a discrimination
might be desirable. It seems to us to be impossible to
solve this problem, as long as the differences between the
glandular kallikreins are not fully understood (12). For
studies on the effects of pig pancreatic kallikrein in ani-
mals other than the pig, we expect from our investigations
that the problem of cross reacting substances will not
arise. Some pharmacological studies on the effects of
kallikrein on dogs after parenteral application are already
published (11).
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